retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Diagram showing the mechanism of action of Retatrutide: The "Triple G" Peptide

The results of these trials have consistently demonstrated the cardiovascular benefits associated with GLP-1 receptor agonists including reductions in major adverse cardiovascular events

Aversion to needles, discomfort with self-injection, or skin problems at the injection site are commonly voiced problems in people with diabetes, and thus, attempts for non-invasive delivery strategies have continued

doi: 10.1111/bcp.14091 124 SeinoYFukushimaMYabeDSeinoYFukushimaMYabeD

Diabetes Care (2015) 38(2):26470

DPP-4i, dipeptidyl peptidase-4 inhibitor

Common side effects Nausea Vomiting Diarrhea Constipation Fatigue Decreased appetite Gas/burping Abdominal cramping Less common but more serious side effects Gallbladder issues Pancreatitis Severe digestive discomfort Kidney concerns in dehydrated individuals Providers often start patients on low doses to improve tolerability